Reversibility of the Enlargement of the Pulmonary Artery in COVID-19 Pneumonia as a Marker of Remission of the Disease.

Publication date: Jan 31, 2024

Coronavirus disease 2019 (COVID-19) pneumonia is associated with extensive pulmonary microangiopathy and the enlargement of the pulmonary artery (PA), while its progression after the remission of the disease has not been investigated yet. The aim was to assess the diametral increase in the PA in COVID-19 pneumonia, as revealed on chest computed tomography (CT), and further investigate its progression. This was a retrospective cohort study of patients with COVID-19 pneumonia, without prior history of pulmonary hypertension, who underwent CT pulmonary angiography before, during, and after the infection. Pulmonary embolism was excluded in all cases. The main PA diameter (MPAD) was assessed in consecutive chest imaging. Statistical analysis was performed with the non-parametric Wilcoxon and Kruskal-Wallis tests, while correlations were performed with the non-parametric Spearman test. A mean +/- SD MPAD of 3. 1 +/- 0. 3 cm in COVID-19 pneumonia was significantly decreased to 2. 8 +/- 0. 3 cm in the post-infectious state after 2-18 months in 31 patients (p-value:

Open Access PDF

Concepts Keywords
Ct chest imaging
Hypertension COVID-19
Microangiopathy pulmonary artery enlargement
Performed pulmonary hypertension


Type Source Name
disease MESH COVID-19
disease MESH Pneumonia
disease IDO history
disease MESH pulmonary hypertension
disease MESH infection
disease MESH Pulmonary embolism
drug DRUGBANK Coenzyme M

Original Article

(Visited 2 times, 1 visits today)